Is Sermorelin Legal in Maryland? How to Access It Legally

What Is Sermorelin and Why Does Its Legal Status Matter?

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile secretion of endogenous growth hormone rather than supplying exogenous GH directly. That mechanism places it in a legally distinct category from recombinant human growth hormone (rhGH), which is a Schedule III controlled substance analog under 21 U.S.C. § 333(e) when prescribed off-label for anti-aging.

The distinction matters for Maryland patients and clinicians. Sermorelin is not itself a controlled substance. Obtaining it still requires a prescription and a compliant pharmacy, but the legal barriers are lower than those surrounding rhGH. Getting this wrong exposes patients to unapproved, unsterile products and exposes clinicians to DEA or state board liability.

Sermorelin vs. Recombinant HGH: A Critical Legal Distinction

The Anabolic Steroid Control Act and subsequent amendments made it a federal crime to prescribe rhGH for anything other than a short list of approved indications, including adult growth hormone deficiency, HIV wasting, and Prader-Willi syndrome. Sermorelin does not appear in those restrictions. Because it works upstream of the pituitary, it is regulated as a compounded drug rather than a controlled substance.

A 2020 analysis in the journal Drugs noted that GHRH analogues "occupy a regulatory space between conventional small-molecule drugs and biologics" and that compounding frameworks remain the primary legal access mechanism in the United States. [1]

Why Patients Seek Sermorelin

Adult growth hormone secretion declines roughly 14 to 15 percent per decade after age 30. [2] Patients and clinicians use Sermorelin to address symptoms attributed to that decline, including reduced lean body mass, increased adiposity, sleep disruption, and diminished recovery. A double-blind, placebo-controlled trial (N=89) published in the Journal of Clinical Endocrinology and Metabolism found that GHRH administration over 6 months significantly increased IGF-1 levels and lean body mass in adults aged 65 to 88. [3]

The Federal Legal Framework for Sermorelin in 2025

Understanding federal rules is the first step before looking at Maryland-specific requirements.

FDA Approval History

The FDA approved Sermorelin acetate (brand name Geref) for diagnostic testing of pituitary function and for treatment of idiopathic growth hormone deficiency in children. Serono withdrew Geref from the commercial market in 2008 for business reasons, not for safety or efficacy concerns. That withdrawal created the current situation: no commercially approved finished-dose Sermorelin product exists, so all clinical use now flows through compounding.

The FDA's website confirms that a market withdrawal for non-safety reasons does not change a drug's safety profile or automatically restrict compounding access. [4]

The FDA Bulks Lists (503A and 503B)

Two federal lists govern which bulk drug substances may be used in compounding.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may use a bulk substance if it appears on the FDA's 503A Bulks List (Category 1, nominated and evaluated), if it has a USP monograph, or if it was commercially available before 1962. [5] Sermorelin does not currently appear on the FDA's Category 1 Withdrawn list, which names substances that compounders may NOT use. That means a 503A pharmacy can compound Sermorelin provided all other 503A requirements are met, including a valid patient-specific prescription.

Under Section 503B, outsourcing facilities must use bulk substances on the FDA's affirmative 503B Bulks List. Sermorelin does appear on the nominated substances list under review, but it has not yet been placed on the affirmative 503B list. Practically, this means a 503B outsourcing facility cannot currently compound Sermorelin without additional FDA clearance. Most legitimate Sermorelin dispensing therefore occurs through 503A pharmacies.

The practical access framework breaks down as follows:

| Access Route | Legal? (2025) | Key Requirement | |---|---|---| | 503A compounding pharmacy | Yes | Patient-specific Rx from licensed prescriber | | 503B outsourcing facility | Not yet affirmatively listed | Awaiting FDA 503B Bulks List addition | | Commercial finished product | No | No FDA-approved product on market | | Research chemical supplier (no Rx) | No | Violates FD&C Act; unapproved drug | | Direct import from overseas | No | Violates FDA import regulations |

What the FDA Has Said About GHRH Peptides

The FDA's 2023 draft guidance on bulk drug substances explicitly grouped several peptides for heightened scrutiny, including BPC-157 and certain melanocortin peptides. Sermorelin was not included in that 2023 draft restriction list. [6] This does not mean Sermorelin is immune from future regulatory action, and any prescriber should monitor FDA guidance updates at least annually.

Maryland State Law: What Governs Sermorelin Dispensing

Maryland adds its own regulatory layer on top of federal rules.

Maryland Board of Pharmacy

The Maryland Board of Pharmacy licenses and disciplines in-state pharmacies under Maryland Code, Health Occupations Article, Title 12. COMAR (Code of Maryland Regulations) Title 10, Subtitle 34 sets compounding standards for Maryland-licensed pharmacies. Any 503A pharmacy dispensing Sermorelin to a Maryland patient must hold a current Maryland pharmacy license or, for out-of-state pharmacies shipping into Maryland, a nonresident pharmacy permit.

Maryland requires out-of-state compounding pharmacies to register with the Board and to comply with USP Chapter 797 sterile compounding standards, which govern beyond-use dating, environmental monitoring, and personnel training. [7] Patients receiving Sermorelin shipped to a Maryland address should verify that the dispensing pharmacy holds this nonresident permit.

Maryland Medical Practice Act

Under Maryland Code, Health Occupations Article, Title 14, a physician must hold a valid Maryland license to prescribe to a Maryland patient. Nurse practitioners prescribing Sermorelin must hold a current CRNP license from the Maryland Board of Nursing and, depending on their practice arrangement, may require a collaborative agreement. Physician assistants require a supervising physician relationship.

Prescribing Sermorelin for "anti-aging" without a documented clinical indication, a current medical history, and IGF-1 laboratory confirmation could expose a Maryland prescriber to a Board complaint for unprofessional conduct under COMAR 10.32.02.

Telehealth Prescribing in Maryland

Maryland permits telehealth prescribing. The Maryland Department of Health confirmed in 2021 guidance that audio-video telehealth encounters can satisfy the prescriber-patient relationship requirement for non-controlled substances. [8] Because Sermorelin is not scheduled, a telehealth prescriber with a Maryland license may order it following a compliant evaluation. That evaluation should include a symptom history, baseline IGF-1, and review of contraindications.

How to Get Sermorelin in Maryland Legally

There are three compliant access paths in Maryland.

Path 1: Maryland-Based Hormone Clinic or Endocrinologist

A small number of anti-aging medicine clinics and endocrinology practices in Maryland offer Sermorelin as part of a broader hormone optimization protocol. The prescriber evaluates baseline labs, including IGF-1, testosterone (if relevant), thyroid panel, and metabolic panel, then sends a prescription to a 503A compounding pharmacy.

This path offers in-person physical examination, which some clinicians consider preferable before initiating injectable therapy. The American Association of Clinical Endocrinology (AACE) 2023 growth hormone deficiency guidelines state: "Diagnosis of adult GHD requires biochemical confirmation; clinical symptoms alone are insufficient." [9] A face-to-face evaluation makes biochemical workup easier to coordinate.

Path 2: Telehealth Prescribers Licensed in Maryland

Several national telehealth platforms employ physicians licensed in Maryland and specialize in hormone therapy including Sermorelin. After an intake questionnaire and lab review, the prescriber conducts a video visit and, if clinically appropriate, sends a prescription to an accredited 503A compounding pharmacy.

Patients should confirm two things before proceeding: that the prescribing physician holds an active Maryland license (verifiable at the Maryland Board of Physicians website) and that the compounding pharmacy holds a Maryland nonresident pharmacy permit.

Path 3: Your Primary Care Physician with Referral or Co-Management

A Maryland primary care physician who has reviewed current compounding regulations can prescribe Sermorelin. Many general practitioners are unfamiliar with 503A compounding mechanics, so providing them with the FDA 503A Bulks framework documentation can accelerate the process. The prescriber writes the order; the patient or practice coordinates with a compliant 503A pharmacy.

What to Expect from a Legitimate Sermorelin Prescription

A legitimate prescription includes a patient-specific label, beyond-use date, sterility testing certificate, and dosing instructions. Typical clinical protocols use 200 to 500 mcg subcutaneous injection administered at bedtime, 5 nights per week, for a minimum trial of 3 to 6 months before re-assessing IGF-1 response. Some protocols combine Sermorelin with GHRP-2 or GHRP-6, though those combinations carry their own regulatory status considerations.

Risks of Obtaining Sermorelin Outside Legal Channels

Patients who purchase Sermorelin from research chemical websites, overseas peptide suppliers, or any source that does not require a prescription are taking medical and legal risks.

Sterility and Purity Concerns

A 2018 study published in JAMA Internal Medicine tested 44 online-purchased compounded drugs and found that 23 percent failed potency testing and 9 percent failed sterility testing. [10] Subcutaneous injection of a non-sterile peptide solution risks abscess, systemic infection, and injection site necrosis.

Legal Exposure for Patients

Possessing a prescription drug without a valid prescription is a misdemeanor under Maryland Health Code Section 5-601 and under 21 U.S.C. § 331. While enforcement against individual patients is rare, the risk exists, particularly if a large quantity is involved or if the substance is imported.

No Clinical Oversight

Without a prescriber, there is no monitoring of IGF-1 or other markers. Supraphysiologic GH stimulation may increase insulin resistance and carries a theoretical risk of stimulating pre-existing neoplasms. The Endocrine Society's 2019 clinical practice guideline on GH therapy states: "Active malignancy is an absolute contraindication to GH or GH-secretagogue therapy." [11] A clinician can screen for these risks. A peptide website cannot.

What Maryland Patients Should Ask Before Starting Sermorelin

Getting a yes-or-no legal answer is not the end of due diligence.

Verifying Your Prescriber

Check the Maryland Board of Physicians license lookup tool at mbp.state.md.us. Confirm the prescriber holds an active Maryland license and has no current disciplinary actions. A prescriber operating from outside Maryland without a Maryland license cannot legally prescribe to you as a Maryland resident.

Verifying Your Pharmacy

Ask the compounding pharmacy for its PCAB (Pharmacy Compounding Accreditation Board) accreditation certificate and its Maryland nonresident pharmacy permit number. PCAB accreditation is voluntary but signals compliance with USP 797 and 795 standards. Unaccredited pharmacies are not automatically non-compliant, but accreditation provides third-party verification.

Reviewing Your Labs Before Starting

Baseline labs should include IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, and, for men over 40, a PSA. Sermorelin can increase IGF-1, which at very high levels has been associated with increased colorectal cancer risk in epidemiological data (relative risk approximately 1.49 per unit increase in IGF-1 SD in a meta-analysis of 16 prospective studies, N=over 8,000). [12] Most patients on physiologic Sermorelin doses do not reach supraphysiologic IGF-1, but baseline measurement establishes a safety reference point.

Monitoring and Ongoing Compliance in Maryland

Starting Sermorelin legally is not a one-time event. Ongoing compliance requires periodic prescriber follow-up.

IGF-1 Monitoring Schedule

Most clinical protocols recheck IGF-1 at 8 to 12 weeks after initiating therapy. The target is typically the upper half of the age-adjusted reference range, not above the upper limit of normal. If IGF-1 exceeds age-adjusted upper limits, dose reduction or temporary discontinuation is appropriate.

Prescription Renewal

A Maryland prescriber cannot simply authorize indefinite refills without reassessment. Maryland's prescribing standards for specialty compounds implicitly require an active prescriber-patient relationship. A reasonable standard is a clinical reassessment at least every 6 months for patients on ongoing injectable peptide therapy.

What Changes Could Affect Legal Access

The FDA revisits its 503A and 503B Bulks Lists periodically. If the FDA moves Sermorelin to the Category 1 Withdrawn list (as it did with BPC-157 in 2023), compounding would become impermissible. Patients and prescribers should check the FDA's compounding drug lists page at least semi-annually. [6]